Pipeline
Avacta will be in the clinic with its lead pre|CISION™ targeted chemotherapy programme in the first half of 2021 and has a pre-clinical pipeline of Affimer® immunotherapy candidates.
Avacta’s long term focus is on achieving a more durable response for patients through synergy of the innate immune response to pre|CISION™ chemotherapies with the adaptive immune response to Affimer® immunotherapies in the form of co-administered combinations and in novel tumour-microenvironment activated drug conjugates (TMAC®).
Its lead Affimer® programme is a PD-L1 antagonist which will form the basis of future bispecifics and TMAC drug conjugates. The lead pre|CISION™ programme is a tumour targeted form of Doxorubicin.
Beyond these two main programmes, the company is exploring a number of I-O antagonists and agonists, and other pre|CISION™ pro-drugs, to support future programmes and partnering.
Click on the red bars in the pipeline infographic below for more information.



